Immunic, Inc. to Participate in Scientific and Investor Conferences in October
September 28, 2021– Three Abstracts, Including One Late-Breaker, to be Presented on IMU-838, the Company’s Selective Oral DHODH Inhibitor, at the 37th…Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19
September 22, 2021– Preclinical Combination Data Suggests Extra-Ordinary Synergy Between Certain DHODH Inhibitors and Nucleoside Analogues – – Combination of IMU-838 and…Immunic, Inc. to Participate in Investor and Scientific Conferences in September
September 8, 2021NEW YORK, September 8, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic, Inc. Reports Second Quarter 2021 Financial Results and Highlights Recent Activity
August 6, 2021– Received FDA Clearance to Initiate Twin IMU-838 Phase 3 ENSURE Trials in Relapsing-Remitting Multiple Sclerosis and Supportive Phase 2…Immunic, Inc. to Participate in Investor Conferences in August
August 3, 2021NEW YORK, August 3, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic, Inc. Announces Closing of $45.0 Million Public Offering
July 19, 2021NEW YORK, July 19, 2021 – Immunic, Inc. (the “Company”) (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective…Immunic, Inc. Announces Pricing of $45 Million Public Offering of Common Stock
July 15, 2021NEW YORK, July 15, 2021 – Immunic, Inc. (the “Company”) (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective…Immunic, Inc. Announces Proposed Public Offering of Common Stock
July 14, 2021NEW YORK, July 14, 2021 – Immunic, Inc. (the “Company”) (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective…Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-935, a Potentially Best-in-Class RORγt Inverse Agonist
July 12, 2021– IMU-935 Has Been Observed In Vitro to Inhibit the Generation of Th17 Cells and Production of IL-17 Cytokines Without…Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis
July 1, 2021– Phase 3 ENSURE Program in Relapsing-Remitting Multiple Sclerosis (RRMS) Comprises Twin Studies Evaluating Efficacy, Safety, and Tolerability of IMU-838…